Recently covered in mainstream media, the antiviral drug Remdesivir may now be a potential treatment for COVID-19 patients admitted into hospitals. The Food and Drug Administration approved the drug for an early use authorization as it is still in clinical trials for testing. In labs, Remdesivir has also been shown to help treat hepatitis and Ebola.
Gilead Sciences, the manufacturer of the drug, was able to get an early use authorization from the FDA so quickly because the drug's safety was thoroughly tested during the Ebola outbreak in 2014, but was halted as other Ebola treatments were proven to be more effective in patients.
As the drug has been talked about in mainstream media in the past month or so, many have wondered what Gilead Sciences will set the price at for the drug. On June 29th, Gilead Sciences said they have set the price at $3,120 for the 5-day treatment for those with private insurance. The price is still unknown but thought to be lower for those with government insurance, and it is unknown what the price tag is for those who are uninsured.
Many doctors and pharmacists have agreed that this is will not provide an end to the pandemic and that only a vaccine will be enough to truly slow the spread of transmission and end this pandemic. Even though this still means that COVID-19 is not over, this news can provide hope for people who need it.